Form 4: Alnylam Pharmaceuticals Director Amy Schulman Acquires Stock Options

Director Amy Schulman acquired 5,228 stock options in Alnylam Pharmaceuticals on May 16, 2024.

Summary

• On May 16, 2024, Amy Schulman, a director of Alnylam Pharmaceuticals, acquired 5,228 stock options.
• The exercise price of these options is $151.22.
• The options vest in full upon the earlier of the first anniversary of the grant date (May 16, 2025) or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• The options expire on May 16, 2034.
• Following the transaction, Amy Schulman directly owns 5,228 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition. The director's acquisition could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a long-term commitment from the director.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates